Answers are grounded in this paper and cite their sources.
Observational analysis evaluates pharmacotherapy rationality in diabetic foot syndrome patients, suggesting cost-efficient practices.
The increasing prevalence of type 2 diabetes mellitus complicated by diabetic foot syndrome and the prescription of high-cost medicines, which are not included in treatment protocols, significantly raise healthcare expenditures and worsen patient outcomes, making the optimisation of pharmacotherapy both a clinical and economic priority. The purpose of this study was to evaluate the rationality of pharmacotherapy for patients with diabetic foot syndrome using an integrated frequency/ABC/VEN analysis. The study applied frequency analysis to assess prescription patterns ATC-classification, ABC-analysis to classify medicines by expenditure levels, and VEN-analysis to determine their therapeutic importance based on national and international treatment guidelines recommendations for type 2 diabetes mellitus. The results demonstrated that etiological and pathogenetic therapies approaches predominated in clinical practice. Antidiabetic agents accounted for the largest share of prescriptions (23%), while antibiotics were essential for managing infectious complications. The integrated frequency/ABC/VEN-analyses revealed that “essential” medicines (44.19%) predominated over “vital” (23.26%) and “non-essential” categories (32.56%), indicating the insufficiently rational prescribing practices in accordance with treatment recommendations. However, a high share of healthcare expenditures was concentrated in a group of high-cost medicines (34.89%), suggesting suboptimal allocation of healthcare resources. The results also highlighted the importance of evidence-based antibiotic selection due to the growing risk of antimicrobial resistance. The study provided a foundation for improving the economic efficiency of pharmacotherapy in patients with diabetic foot syndrome by supporting rational prescribing, optimisation of healthcare expenditures, and the promotion of cost-effective Ukrainian medicines alternatives
No takes yet. Share an insight, caveat, or question.
Pokotylo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: